CORD-19:16a812de72963ceda960a168236e8dbe91832d45 / 70592-70760 JSONTXT

{"project":"CORD-19-SciBite-sentences","denotations":[{"id":"T789","span":{"begin":0,"end":168},"obj":"http://purl.obolibrary.org/obo/HP0002180"},{"id":"T790","span":{"begin":0,"end":168},"obj":"http://purl.obolibrary.org/obo/HP0001297"},{"id":"T791","span":{"begin":0,"end":168},"obj":"https://id.nlm.nih.gov/mesh/D006801"},{"id":"T793","span":{"begin":0,"end":168},"obj":"https://id.nlm.nih.gov/mesh/D013119"},{"id":"T795","span":{"begin":0,"end":168},"obj":"SDI0027"},{"id":"T796","span":{"begin":0,"end":168},"obj":"https://id.nlm.nih.gov/mesh/D020521"}],"attributes":[{"id":"A789","pred":"class","subj":"T789","obj":"HPO"},{"id":"A790","pred":"class","subj":"T790","obj":"HPO"},{"id":"A791","pred":"class","subj":"T791","obj":"SPECIES"},{"id":"A793","pred":"class","subj":"T793","obj":"INDICATION"},{"id":"A795","pred":"class","subj":"T795","obj":"INDICATION"},{"id":"A796","pred":"class","subj":"T796","obj":"INDICATION"}],"text":"Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as MS, spinal cord injury, neurodegeneration, and stroke."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T108","span":{"begin":0,"end":168},"obj":"Sentence"}],"text":"Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as MS, spinal cord injury, neurodegeneration, and stroke."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T350","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"TextSentencer_T350","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"T47869","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as MS, spinal cord injury, neurodegeneration, and stroke."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T201","span":{"begin":114,"end":116},"obj":"Disease"},{"id":"T202","span":{"begin":118,"end":136},"obj":"Disease"},{"id":"T203","span":{"begin":130,"end":136},"obj":"Disease"},{"id":"T204","span":{"begin":161,"end":167},"obj":"Disease"}],"attributes":[{"id":"A201","pred":"mondo_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A202","pred":"mondo_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/MONDO_0043797"},{"id":"A203","pred":"mondo_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A204","pred":"mondo_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A205","pred":"mondo_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"}],"text":"Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as MS, spinal cord injury, neurodegeneration, and stroke."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T97","span":{"begin":138,"end":155},"obj":"Phenotype"},{"id":"T98","span":{"begin":161,"end":167},"obj":"Phenotype"}],"attributes":[{"id":"A97","pred":"hp_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/HP_0002180"},{"id":"A98","pred":"hp_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/HP_0001297"}],"text":"Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as MS, spinal cord injury, neurodegeneration, and stroke."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T151","span":{"begin":118,"end":129},"obj":"Body_part"}],"attributes":[{"id":"A151","pred":"uberon_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/UBERON_0002240"}],"text":"Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as MS, spinal cord injury, neurodegeneration, and stroke."}